<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 (PI3K&delta; Inhibitor)<br> in Combination With Ruxolitinib in Subjects With Myelofibrosis
		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-showx2" href="images/study-rationale/Incyte ASCO 2017 mockup_1200a_PI3K-JAK-STAT_MF_v2.jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 bg-blue primary-objectives-nav5">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav5">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav5">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top5" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content5">
				<div id="po5"></div>
				<!-- section 1 -->
				<div class="scroll-wrapper" style="position: relative;">
					<div id="po5">
						<div class="absolute-cen">						
						<h3 id="po5">Primary objectives:</h3>
						<ul>
						<li><strong>Part 1:</strong> Evaluate safety and tolerability of INCB050465 (PI3K&delta; inhibitor) in combination with ruxolitinib in subjects with MF and select a dose for further evaluation</li>
						<li><strong>Part 2:</strong> Evaluate efficacy of the combination on spleen volume reduction</li>
						</ul>
						<br>
						<h3>secondary objectives:</h3>
						<ul id="po5">
						<li>Evaluate efficacy of INCB050465 in combination with ruxolitinib on MF symptoms</li>
						<li>Evaluate efficacy of combination on response using International Working Group–Myeloproliferative Neoplasms Research and Treatment criteria</li>
						<li>Assess pharmacokinetics</li>
						</ul>
						</div>
					</div>
					<div id="po5"></div>
					<!-- section 2 -->
					<div id="sd5">
						<div class="absolute-cen">
						<h3>Study Design</h3>

						<img class="img-responsive" src="images/study-design/ash-incyte-study-design-graphic.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
						</div>
					</div>
					
					<!-- section 3 -->
					<div id="kiec5">
						<div class="absolute-cen">
						<h3>Key inclusion criteria:</h3>
						<ul>
							<li>Age ≥18 years</li>
							<li>Diagnosis of primary MF, post–polycythemia vera MF, or post–essential thrombocythemia MF</li>
							<li>Treated with ruxolitinib for ≥6 months with stable dose for ≥8 weeks</li>
							<li>Palpable splenomegaly >10 cm below left subcostal margin or splenomegaly 5 to 10 cm below left subcostal margin and active symptoms of MF</li>
							<li>Subjects with an Eastern Cooperative Oncology Group performance status of <span class="nowrap">0, 1, or 2</span></li>
						</ul>
						<br>
						<h3>Key exclusion criteria:</h3>
						<ul>
							<li>Recent history of inadequate bone marrow reserve</li>
							<li>Inadequate liver or renal function</li>
							<li>Use of experimental drug therapy for MF or any other standard drug (eg, danazol, hydroxyurea) with the exception of ruxolitinib within 6 months of starting study (combination) therapy</li>
						</ul>
						</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm5" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
	<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p>MF = myelofibrosis, PI3K&delta; = phosphatidylinositol-3 kinase delta</p>
</div>